Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on a new combination ...

AbbVie's long-acting anti-IL-13 antibody zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

Eli Lilly's triple G agonist retatrutide has achieved impressive weight loss in patients with type 2 diabetes and obesity, ...

MSD has signed a global license agreement for a KRAS G12D inhibitor from China's SciBrunch Therapeutics, paying $400 million ...

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

Other candidates in its pipeline include injectable GIP/GLP-1 agonist enicepatide, injectable amylin analogue petrelintide, ...

The pharmaceutical industry is undergoing an era of innovation and change. Over the next few years, companies will need to ...